991-P: Association between Glucose Abnormality Status and Previous Cerebrovascular Disease (CVD) on Subsequent CVD in Japanese Men Using Real-World Data

Abstract

Although a history of both CVD and glucose abnormality are risk factors for CVD, few large studies have examined the association between prior CVD and glucose abnormality on subsequent CVD in the same cohort. Thus, we compared the impact of prior CVD, glucose abnormality status and their combinations on subsequent CVD using real-world data. Men aged 18-72 years and followed for ≥3 years between 2008 and 2016 were classified as normoglycemia (n = 210,434), borderline glycemia (n = 119,933) or diabetes (DM) (n = 33,260) defined by fasting plasma glucose, HbA1c, and antidiabetic drug prescription. Prior and subsequent CVD were identified according to claims using ICD-10 codes, medical procedures and questionnaires. Cox regression showed that CVD+ conferred a 5- to 8-fold excess risk for CVD regardless of glucose abnormality status (Table). Borderline glycemia did not influence risk of CVD in both prior CVD+ and CVD- status, whereas DM affected subsequent CVD in CVD-. In CVD-/DM, age, current smoking, SBP, HDL-C and HbA1c were associated with risk of CVD, but only SBP was related to CVD risk in CVD+/DM. Impacts of glucose tolerance and glycemic control on risk of CVD were much less than prior CVD. SBP was more strongly associated with CVD risk than glycemia in DM with prior CVD. Individualized treatment strategies should consider glucose tolerance status and prior CVD. Disclosure M. Oe: Employee; Self; Kowa Company, Ltd. T. Yamada: None. H. Sone: Research Support; Self; Astellas Pharma Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Novo Nordisk, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co. K. Fujihara: None. M. H. Yamada: None. T. Osawa: None. M. Kitazawa: None. Y. Matsubayashi: None. T. Sato: None. Y. Yaguchi: None. M. Iwanaga: None.